BFM
KNSA icon

Boothbay Fund Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Boothbay Fund Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,783
Closed -$297K – 1665
2020
Q4 		$297K Sell
16,783
-23,120
-58% -$406K 0.01% 953
2020
Q3 		$611K Buy
+39,903
New +$749K 0.04% 591
2020
Q2 		– Sell
-52,459
Closed -$812K – 1043
2020
Q1 		$812K Buy
52,459
+8,459
+19% +$132K 0.07% 347
2019
Q4 		$487K Buy
+44,000
New +$382K 0.04% 491

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Boothbay Fund Management's KNSA Position: Q1 2021 in Review

Boothbay Fund Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2021, closing a stake of 16,783 shares — an estimated $297K sold.

Boothbay Fund Management first reported a position in KNSA in Q4 2019 and held it in 4 quarters. The position peaked at $812K in Q1 2020. 105 funds tracked by Wall St. Rank hold KNSA as of Q1 2021.

  • Boothbay Fund Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 16,783 Kiniksa Pharmaceuticals shares in Q1 2021, an estimated $297K.
  • Boothbay Fund Management first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Boothbay Fund Management's Kiniksa Pharmaceuticals position peaked at $812K in Q1 2020.
  • 105 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2021.

Based on Boothbay Fund Management's 13F filing for Q1 2021, filed 17 May 2021.